An open studio Published in 2018 He evaluated AuraSTOP® in continuous use in the case of migraine with aura in subjects with high frequency of attacks.
The study enrolled 18 subjects, with an average age of 28.5 ± 1.5 years (10 females and 8 males), all with a diagnosis of migraine with aura for at least 6 months and a monthly crisis frequency of between 5 and 20 episodes.
The main endpoints were: monthly frequency of migraine attacks with aura, aura duration, aura-related disability and pain intensity.
The safety of administration was monitored by assessing the rate of interruption and the presence of unwanted events. Subjects kept a clinical diary to record the characteristics of the aura and headache attacks, including the duration of the aura, the disability (on a scale of 0 to 5) and the intensity of the pain (on a VAS scale). At the end of the observation period, each person received an AuraSTOP® blister with the instruction to take two tablets a day for 90 days.
During the period of taking AuraSTOP©, significant improvements were observed with respect to the observation period and the following results were obtained:
No patient reported unwanted events related to the use of AuraSTOP®, and no study withdrawals were recorded for product-related problems.
The intake of AuraSTOP® has improved several endpoints under the study, such as migraine attacks with aura, with significant reductions in the frequency of episodes, in the duration of the aura and in related disability, without reported unwanted events.
Limitations: The methodological limits (absence of control group, small sample, subjective measures and nature of the observational study) prevent definitive conclusions from being drawn. To confirm these results, randomized, placebo-controlled, and adequate statistical power studies are needed.
(Dal Volta G., et al. Comparison of the effect of Tanacethum parthenium, 5-hydroxy tryptophan, and magnesium (AuraSTOP) versus magnesium alone on aura phenomenon and ITS Evolution. Pain Research and Management. 2019;6320163)
(Mainardi F., et al. Efficacy of a combination of tanacetum parthenium, 5-hydroxy tryptohan and magnesium (AuraSTOP) in Episodic migraine prevention: a multicentric Observational Study Open Access Library Journal 2018;5,E4765).
(Ferrare P., et A. Tanacetum, Parthenium, Griffonia simplicifolia and magnesium as symptomatic and prophylactic treatment for headache in Paediatric Patients. International Journal of Neurology and Braind Disorders ISSN 2377-1348).
(Zavarise P., et al. Combination of Tanacethum Partenium, 5-Hydroxitriptophan (5-HTTP) and Magnesium in the Prophylaxis of Episodic migraine without aura (Aurastop®) An observational study.
